Results 211 to 220 of about 30,785 (250)
Impact of reconstruction type on late gadolinium enhancement scar quantification at 3-Tesla: Magnitude vs. phase-sensitive inversion recovery. [PDF]
J Cardiovasc Magn ResonMoafi A +5 more
europepmc +1 more source
Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer. [PDF]
Pathol IntHodgson K +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Heart Failure Clinics, 2018
Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 receptor family, whose role was originally established in the context of inflammatory and autoimmune diseases. More recently, testing for ST2 has been used in the setting of cardiovascular disease.
Cian Mccarthy, James Januzzi
exaly +3 more sources
Suppression of tumorigenicity 2 (ST2) is a member of the interleukin (IL)-1 receptor family, whose role was originally established in the context of inflammatory and autoimmune diseases. More recently, testing for ST2 has been used in the setting of cardiovascular disease.
Cian Mccarthy, James Januzzi
exaly +3 more sources
Molecular cloning of the chicken ST2 gene and a novel variant form of the ST2 gene product, ST2LV
Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004The ST2 gene encodes receptor-like molecules that are very similar to the interleukin-1 receptors. Three types of ST2 gene products, ST2, ST2L, and ST2V, can be produced by alternative splicing. In the course of cloning the chicken ST2 and ST2L cDNAs, we identified a novel variant cDNA other than ST2, ST2L, or ST2V, and tentatively named it ST2LV ...
Ken Yanagisawa +2 more
exaly +3 more sources
The Biology of ST2: The International ST2 Consensus Panel
The American Journal of Cardiology, 2015ST2 is a member of the interleukin 1 receptor family with 2 main isoforms: transmembrane or cellular (ST2L) and soluble or circulating (sST2) forms. ST2 is the receptor of the IL-33, which is an IL-1-like cytokine that can be secreted by living cells in response to cell damage.
Domingo A, Pascual-Figal +1 more
+7 more sources
The American Journal of Cardiology, 2015
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of
Ednan K, Bajwa +2 more
openaire +2 more sources
In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a clinical biomarker for cardiovascular disease. However, much preclinical data points to involvement of the ST2 pathway in inflammation, and specifically in pulmonary inflammation. This report summarizes the current body of clinical data suggesting the potential role of
Ednan K, Bajwa +2 more
openaire +2 more sources
Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load [PDF]
Journal of the American College of Cardiology, 2008 ObjectivesThis study was designed to investigate: 1) relationships between serum ST2 levels and hemodynamic/neurohormonal variables; 2) myocardial ST2 production; and the 3) expression of ST2, membrane-anchored ST2L, and its ligand, interleukin (IL)-33 ...
Ellen Weinberg +2 more
exaly +2 more sources
Soluble ST2—Analytical Considerations
The American Journal of Cardiology, 2015Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L.
Thomas, Mueller, Allan S, Jaffe
openaire +2 more sources
ST2 and Prognosis in Acutely Decompensated Heart Failure: The International ST2 Consensus Panel
The American Journal of Cardiology, 2015ST2 is a member of the interleukin (IL) 1 receptor family that exists in 2 forms, a transmembrane receptor (ST2L) and a soluble receptor (sST2). The ligand of ST2 is IL-33, known to be involved in reducing tissue fibrosis and myocyte hypertrophy in mechanically strained hearts.
Januzzi, James L. +2 more
openaire +2 more sources